Research location
Ridgewood
New Jersey, United States
Advertisement
Research activity in Ridgewood
New Jersey, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 135 trials and 153 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Ridgewood
135 linked trials · page 1 of 3A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)NCT06976203 · 2025-07-21 · 1 site observation
RECRUITING
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)NCT07033494 · 2025-07-16 · 1 site observation
RECRUITING
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease StudiesNCT07177352 · 2025-07-02 · 1 site observation
RECRUITING
E-Mindfulness Approaches for Living After Breast CancerNCT06748222 · 2025-06-27 · 1 site observation
RECRUITING
Phase IIIb Study of Ribociclib + ET in Early Breast CancerNCT05827081 · 2024-02-28 · 1 site observation
RECRUITING
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenTNCT06059638 · 2023-12-27 · 1 site observation
RECRUITING
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25NCT05879926 · 2023-10-18 · 2 site observations
RECRUITING
Left vs Left Randomized Clinical TrialNCT05650658 · 2023-09-13 · 1 site observation
RECRUITING
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus PembrolizumabNCT05812807 · 2023-06-14 · 1 site observation
RECRUITING
His-Bundle Corrective Pacing in Heart FailureNCT05265520 · 2022-12-02 · 1 site observation
RECRUITING
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerNCT04181060 · 2020-12-28 · 2 site observations
RECRUITING
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])NCT04267848 · 2020-06-16 · 2 site observations
RECRUITING
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy ProductsNCT00271180 · 1983-01-01 · 1 site observation
RECRUITING
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's DiseaseNCT07169578 · 2025-09-17 · 1 site observation
ACTIVE_NOT_RECRUITING
Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam TrialNCT06671912 · 2025-02-19 · 1 site observation
SUSPENDED
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the BrainNCT06500455 · 2024-12-12 · 1 site observation
ACTIVE_NOT_RECRUITING
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung CancerNCT06632327 · 2024-12-11 · 2 site observations
ACTIVE_NOT_RECRUITING
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)NCT06653153 · 2024-10-24 · 1 site observation
ACTIVE_NOT_RECRUITING
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and InflammationNCT05636176 · 2023-05-08 · 2 site observations
TERMINATED
Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung CancerNCT05693090 · 2023-02-01 · 1 site observation
WITHDRAWN
Clinical Investigation of the da Vinci Surgical SystemNCT05682742 · 2022-12-12 · 1 site observation
ACTIVE_NOT_RECRUITING
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung CancerNCT05221840 · 2022-02-07 · 1 site observation
ACTIVE_NOT_RECRUITING
Screening for High Frequency Malignant DiseaseNCT05117840 · 2022-01-13 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)NCT05093933 · 2021-11-02 · 1 site observation
COMPLETED
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)NCT04964934 · 2021-06-30 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast CancerNCT04752332 · 2021-05-10 · 1 site observation
TERMINATED
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT TrialNCT04513717 · 2021-01-21 · 1 site observation
ACTIVE_NOT_RECRUITING
Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence (REBALANCE Registry)NCT04502316 · 2020-06-26 · 1 site observation
TERMINATED
Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung CancerNCT04262856 · 2020-05-28 · 1 site observation
COMPLETED
Post Approval Study (PAS) of the OPTIMIZER Smart and CCM TherapyNCT03970343 · 2020-01-21 · 1 site observation
ACTIVE_NOT_RECRUITING
PROACTIVE-HF IDE Trial Heart Failure NYHA Class IIINCT04089059 · 2020-01-10 · 1 site observation
ACTIVE_NOT_RECRUITING
Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial CancerNCT03989362 · 2019-06-06 · 1 site observation
COMPLETED
Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast CancerNCT03199885 · 2019-04-05 · 2 site observations
TERMINATED
DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection FractionNCT03877224 · 2019-04-04 · 1 site observation
COMPLETED
Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast CancerNCT03598257 · 2019-01-18 · 1 site observation
ACTIVE_NOT_RECRUITING
Physiologic Pacing RegistryNCT03719040 · 2018-11-27 · 1 site observation
COMPLETED
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid TumorsNCT03375320 · 2018-10-26 · 1 site observation
ACTIVE_NOT_RECRUITING
Reducing Lung CongestIon Symptoms in Advanced Heart FailureNCT03499236 · 2018-09-19 · 1 site observation
ACTIVE_NOT_RECRUITING
Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)NCT03521934 · 2018-06-15 · 1 site observation
TERMINATED
A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory MelanomaNCT03445533 · 2018-05-30 · 1 site observation
TERMINATED
Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung CancerNCT03382561 · 2018-05-21 · 2 site observations
COMPLETED
Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBCNCT03326674 · 2017-12-21 · 1 site observation
TERMINATED
Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung CancerNCT03373760 · 2017-11-30 · 2 site observations
COMPLETED
A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)NCT03254485 · 2017-11-07 · 1 site observation
COMPLETED
Attain Stability™ Quad Clinical StudyNCT03099655 · 2017-07-07 · 1 site observation
COMPLETED
Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart FailureNCT03035474 · 2017-04-21 · 1 site observation
COMPLETED
Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)NCT03071692 · 2017-03-23 · 1 site observation
TERMINATED
Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-StudyNCT03037931 · 2017-03-15 · 1 site observation
COMPLETED
Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung CancerNCT03377556 · 2017-03-03 · 2 site observations
COMPLETED
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast CancerNCT02954874 · 2017-01-18 · 1 site observation
ACTIVE_NOT_RECRUITING
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.